Corcept Therapeutics CORT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $761.41M+12.8% | $675.04M+39.9% | $482.38M+20.0% | $401.86M+9.8% | ||
| $12.98M+19.3% | $10.88M+67.9% | $6.48M+20.4% | $5.39M+2.0% | ||
| $254.91M+3.2% | $246.89M+33.9% | $184.35M+40.7% | $130.99M+15.0% | ||
| $448.73M+60.1% | $280.32M+52.1% | $184.26M+20.6% | $152.85M+24.9% | ||
| $716.61M+33.2% | $538.09M+43.5% | $375.09M+29.7% | $289.22M+19.8% | ||
| $44.8M-67.3% | $136.95M+27.7% | $107.28M-4.8% | $112.63M-9.5% | ||
| 5.9%-14.4pp | 20.3%-2.0pp | 22.2%-5.8pp | 28%-6.0pp | ||
| $21.67M-11.7% | $24.54M+42.0% | $17.28M+386% | $3.56M+572% | ||
| $66.46M-58.8% | $161.49M+29.7% | $124.56M+7.2% | $116.19M-7.1% | ||
| -$33.19M-264% | $20.28M+10.1% | $18.42M+24.7% | $14.77M+18.2% | ||
| $99.65M-29.4% | $141.21M+33.0% | $106.14M+4.7% | $101.42M-9.9% | ||
| 13.1%-7.8pp | 20.9%-1.1pp | 22%-3.2pp | 25.2%-5.5pp | ||
| $0.82-33.3% | $1.23+29.5% | $0.95+8.0% | $0.88-1.1% | ||
| $45.95M-66.6% | $137.75M+27.2% | $108.32M-4.9% | $113.89M-10.7% | ||
| 6%-14.4pp | 20.4%-2.1pp | 22.5%-5.9pp | 28.3%-6.5pp | ||
| $44.8M-67.3% | $136.95M+27.7% | $107.28M-4.8% | $112.63M-9.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Corcept Therapeutics's revenue?
- Corcept Therapeutics (CORT) generated $769.1M in revenue over the trailing twelve months, up 12.2% year over year.
- Is Corcept Therapeutics profitable?
- Corcept Therapeutics reported $47.3M in net income over the trailing twelve months, a 6.2% net margin.
- What are Corcept Therapeutics's profit margins?
- Gross margin is 98.3% and operating margin is -1.1%, with a 6.2% net margin.
- What is Corcept Therapeutics's earnings per share?
- Corcept Therapeutics's diluted EPS over the trailing twelve months is $0.35.
- Where does Corcept Therapeutics's income statement data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
